These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 26341051)
1. Role of mTOR in glioblastoma. Duzgun Z; Eroglu Z; Biray Avci C Gene; 2016 Jan; 575(2 Pt 1):187-90. PubMed ID: 26341051 [TBL] [Abstract][Full Text] [Related]
2. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes. Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674 [TBL] [Abstract][Full Text] [Related]
3. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid. Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261 [TBL] [Abstract][Full Text] [Related]
4. Defining the role of mTOR pathway in the regulation of stem cells of glioblastoma. Jhanwar-Uniyal M; Gellerson O; Bree J; Das M; Kleinman G; Gandhi CD Adv Biol Regul; 2023 May; 88():100946. PubMed ID: 36658088 [TBL] [Abstract][Full Text] [Related]
5. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Mabuchi S; Kuroda H; Takahashi R; Sasano T Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064 [TBL] [Abstract][Full Text] [Related]
6. A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma. Laks DR; Oses-Prieto JA; Alvarado AG; Nakashima J; Chand S; Azzam DB; Gholkar AA; Sperry J; Ludwig K; Condro MC; Nazarian S; Cardenas A; Shih MYS; Damoiseaux R; France B; Orozco N; Visnyei K; Crisman TJ; Gao F; Torres JZ; Coppola G; Burlingame AL; Kornblum HI Neuro Oncol; 2018 May; 20(6):764-775. PubMed ID: 29136244 [TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness. Artinian N; Cloninger C; Holmes B; Benavides-Serrato A; Bashir T; Gera J J Biol Chem; 2015 Aug; 290(32):19387-401. PubMed ID: 25998128 [TBL] [Abstract][Full Text] [Related]
8. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Li X; Wu C; Chen N; Gu H; Yen A; Cao L; Wang E; Wang L Oncotarget; 2016 May; 7(22):33440-50. PubMed ID: 26967052 [TBL] [Abstract][Full Text] [Related]
9. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway. Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190 [TBL] [Abstract][Full Text] [Related]
10. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma. Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240 [TBL] [Abstract][Full Text] [Related]
11. Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding. Sami A; Karsy M Tumour Biol; 2013 Aug; 34(4):1991-2002. PubMed ID: 23625692 [TBL] [Abstract][Full Text] [Related]
12. Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma. Benavides-Serrato A; Lee J; Holmes B; Landon KA; Bashir T; Jung ME; Lichtenstein A; Gera J PLoS One; 2017; 12(4):e0176599. PubMed ID: 28453552 [TBL] [Abstract][Full Text] [Related]
13. Will kinase inhibitors make it as glioblastoma drugs? Mellinghoff IK; Schultz N; Mischel PS; Cloughesy TF Curr Top Microbiol Immunol; 2012; 355():135-69. PubMed ID: 22015553 [TBL] [Abstract][Full Text] [Related]
14. A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma. Read RD; Fenton TR; Gomez GG; Wykosky J; Vandenberg SR; Babic I; Iwanami A; Yang H; Cavenee WK; Mischel PS; Furnari FB; Thomas JB PLoS Genet; 2013; 9(2):e1003253. PubMed ID: 23459592 [TBL] [Abstract][Full Text] [Related]
15. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma. Beck JT; Ismail A; Tolomeo C Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117 [TBL] [Abstract][Full Text] [Related]
16. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Sunayama J; Matsuda K; Sato A; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C Stem Cells; 2010 Nov; 28(11):1930-9. PubMed ID: 20857497 [TBL] [Abstract][Full Text] [Related]
17. A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma. Fan Q; Aksoy O; Wong RA; Ilkhanizadeh S; Novotny CJ; Gustafson WC; Truong AY; Cayanan G; Simonds EF; Haas-Kogan D; Phillips JJ; Nicolaides T; Okaniwa M; Shokat KM; Weiss WA Cancer Cell; 2017 Mar; 31(3):424-435. PubMed ID: 28292440 [TBL] [Abstract][Full Text] [Related]
18. Structure-based grafting and identification of kinase-inhibitors to target mTOR signaling pathway as potential therapeutics for glioblastoma. Cui YH; Chen J; Xu T; Tian HL Comput Biol Chem; 2015 Feb; 54():57-65. PubMed ID: 25625417 [TBL] [Abstract][Full Text] [Related]
19. Phytochemical modulation of the Akt/mTOR pathway and its potential use in cutaneous disease. Leo MS; Sivamani RK Arch Dermatol Res; 2014 Dec; 306(10):861-71. PubMed ID: 24972910 [TBL] [Abstract][Full Text] [Related]
20. Inhibiting 4EBP1 in Glioblastoma. Fan QW; Nicolaides TP; Weiss WA Clin Cancer Res; 2018 Jan; 24(1):14-21. PubMed ID: 28696243 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]